It was short and sweet. Focused on the Satipharm product and...

It was short and sweet. Focused on the Satipharm product and trying to get as many participants as possible for the clinical study.Jcurve already replied but to confirm they entered into a new 15 mill working capital facility with NAB on the 22/04/22 and renegotiated the 50 mill loan so no repayments until May 2024. I spent a lot more time looking at numbers before something I haven’t got the energy for right now but I remember they had enough money (judging from the last quarterly release and taking into account increased expenses) to keep going until EOFY 22/23.Being optimistic I currently feel they have the potential to break even next year. Hopefully then also increasing revenues further to comfortably repay loans (of course all dependent on the S3 registration).